Quest Diagnostics (DGX) demonstrated exceptional growth and made several strategic moves as seen from reports. Quest's shares were bolstered by purchasers like
Janus Henderson and
Tidal Investments. The health&diagnostics company has been recognized as an inclusive workplace for the seventh consecutive year, showing its commitment to diversity. The financial performance for Q4 and full year 2023 will be published on Feb 1, 2024, while guidance for 2024 has been raised. The company achieved new highs for its stock, reaching $151.27 twice and suggested undervaluation.
Acquisitions include Outreach Laboratory Services of
OhioHealth, select assets of
PathAI Diagnostics and
LifeLabs from OMERS. These acquisitions highlight the company's expansion in pathology aided by AI and boosting diagnostic services in Canada. The company also plans to acquire lab assets from
Allina Health. Senior leadership roles were announced with Murali Balakumar and Yuri A. Fesko, M.D. being appointed. A partnership with Broad Clinical Labs aims to evaluate whole genome sequencing for developmental delay. The company plans to increase its dividend to $0.75 per share after Q4, 2023 results.
Quest Diagnostics DGX News Analytics from Wed, 20 Dec 2023 08:00:00 GMT to Sun, 04 Aug 2024 19:45:05 GMT -
Rating 9
- Innovation 6
- Information 8
- Rumor -4
